138
Participants
Start Date
March 31, 2020
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
AK105
AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Anlotinib
A multi-target receptor tyrosine kinase inhibitor.
Beijing Hospital, Beijing
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing
Peking University International Hospital, Beijing
The Third Affiliated Hospital of Harbin Medical University, Harbin
Jiangsu Cancer Hospital, Nanjing
Tianjin Cancer Hospital, Tianjin
The Second Affiliated Hospital of The PLA Air Force Medical University, Xi’an
Shanxi Cancer Hospital, Xi’an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY